[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Dirk
D
Einecke
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy; D000577:Amides; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000517:prevention & control*; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000627:therapeutic use; D004952:Esters; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013438:Sulfhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use
D000577:Amides; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D015507:Drugs, Investigational; D004952:Esters; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D023303:Oxazolidinones; D013438:Sulfhydryl Compounds; D001569:Benzodiazepines; D009525:Niacin; C411602:dalcetrapib; C568301:evacetrapib; C530884:anacetrapib